Tanios S. Bekaii-Saab, MD, on Recent Updates in GI Malignancies at ASCO 2021

Video

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, to discuss recent updates in the treatment of gastrointestinal malignancies.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, to discuss recent updates in the treatment of gastrointestinal (GI) malignancies. Specifically, a number of developments in chemoimmunotherapy have been made for patients with gastroesophageal cancers, offering the potential to influence the standard of care in certain tumor types.

Transcript:

Overall, in GI cancers, we have [seen] some really incredible data. Starting with non–colorectal cancers, we have seen some of the fastest improvements, especially in the world of immunotherapy, in gastroesophageal cancers.

We are moving now to chemoimmunotherapy. Your chemotherapy of choice in the United States would be 5-fluorouracil, leucovorin, and oxaliplatin plus your agent of choice, which would be nivolumab [Opdivo] or pembrolizumab [Keytruda]. We have frankly continued to see consistently that adding a PD-1 inhibitor to chemotherapy is the way to go. Of course, there remain some questions: Do we sequence better? Do we change the sequence? Do we have to give them together at the same time? Can we go with just the PD-1 inhibitor and then maybe add the chemotherapy? The sequencing questions will remain, but it is undeniable that the first line now belongs to chemoimmunotherapy. There was an interesting study, albeit just in squamous cell [histology]—we are waiting for more data ultimately to show up in adenocarcinomas and others—that suggests that nivolumab and ipilimumab [Yervoy] may also be an option. It did not perform better than nivolumab plus chemotherapy, by the way, but it did perform better than chemotherapy alone.

Reference

Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. J Clin Oncol. 2021;39(suppl 15):LBA4001. doi:10.1200/JCO.2021.39.15_suppl.LBA4001

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Related Content